BRCA1 and BRCA2 germline variant screening using Sanger DNA sequencing or NGS is well established in clinical practice and is used primarily for the determination of hereditary breast and ovarian cancer risk [30-33]. This evidence concerns the gene BRCA2 and ovarian carcinoma.